Operates as a biopharmaceutical company
Zeltia SA is a holding company, which develops marine-based drugs in the field of oncology.
It operates through the Biopharmaceuticals and Consumer Chemicals segments.
The Biopharmaceuticals segment engages in the research and marketing of anti-tumor drugs, diagnosis kits, and development of therapies based on reducing or silencing gene expression.
The Consumer Chemicals segment produces and markets insecticides and air fresheners for household use, household products, wood treatment and decoration products, paints, and related products.
The company was founded on August 3, 1939 and is headquartered in Madrid, Spain.
|José Maria Fernández de Sousa-Faro, PhD, MBA ||14,269,511||
|Mera Sandra Ortega ||11,110,333||
|Montserrat Andrade Detrell MD, PhD ||10,254,841||
|Safoles SA ||8,615,205||
|Norges Bank Investment Management ||6,383,289||
|Kutxabank SA ||4,671,000||
|José Luis Fernández Puentes, PhD ||3,209,426||
|Santiago Alfredo Fernández Puentes ||3,074,810||
|JPMorgan Asset Management (UK) Ltd. ||3,016,224||
|Dimensional Fund Advisors LP ||1,532,551||
|Company contact information|
Plaza Descubridor Diego de Ordás, 3
Phone : +34.91.444.45.00
Fax : +34.91.593.29.94
Web : www.zeltia.es
© 2015 Factset